PMID- 15700308
OWN - NLM
STAT- MEDLINE
DCOM- 20050705
LR  - 20160303
IS  - 0020-7136 (Print)
IS  - 0020-7136 (Linking)
VI  - 115
IP  - 4
DP  - 2005 Jul 1
TI  - RASSF1A is not appropriate as an early detection marker or a prognostic marker 
      for non-small cell lung cancer.
PG  - 575-81
AB  - Aberrant methylation of several tumor suppressor genes often occurs during the 
      pathogenesis of lung cancer. RASSF1A is one of the tumor suppressor genes, and it 
      is frequently inactivated by hypermethylation of its promoter region in a variety 
      of human cancers, including lung cancer. It has recently been suggested that 
      RASSF1A methylation was frequently observed in poorly differentiated tumors, and 
      that it was correlated with adverse survival in lung adenocarcinoma (Tomizawa Y, 
      et al., Clin Cancer Res 2002;8:2362-8). In this study, we investigated the 
      pathogenetic and clinicopathologic significance of RASSF1A methylation for the 
      development and/or progression of non small cell lung cancer (NSCLC). We examined 
      116 cases of NSCLC for the methylation status of RASSF1A. Methylation-specific 
      analysis demonstrated that 40.5% (47 of 116) of the cases were methylated at the 
      CpG sites in the promoter. Methylation of RASSF1A was associated with cellular 
      differentiation (p = 0.0244) and it was related to survival (p = 0.0276). 
      However, there was no association between RASSF1A methylation and the individual 
      clinicopathologic features: TNM stage (p > 0.1), recurrence (p > 0.1), lymphatic 
      permeation (p > 0.1) and smoking duration time (p > 0.1). Furthermore, we 
      analyzed RASSF1A's probability as a prognostic marker by using stepwise Cox 
      proportional hazard regression testing. As a result, the stage proved to be the 
      most important factor (p = 0.0089), more than any other factors such as age, 
      gender, cell type, methylation status, differentiation, smoking duration time, 
      tumor size and lymph node permeation. There was no other significant factor other 
      than stage and age. These results show that epigenetic inactivation of RASSF1A 
      cannot be a prognostic marker of NSCLC.
CI  - Copyright 2005 Wiley-Liss, Inc.
FAU - Choi, Naeyun
AU  - Choi N
AD  - Cancer Research Center, Center for Clinical Research, Samsung Biomedical Research 
      Institute, Sungkyunkwan University School of Medicine, Seoul, South Korea.
FAU - Son, Dae-Soon
AU  - Son DS
FAU - Song, Inseung
AU  - Song I
FAU - Lee, Hye-Sook
AU  - Lee HS
FAU - Lim, Yoo-Sung
AU  - Lim YS
FAU - Song, Min Sup
AU  - Song MS
FAU - Lim, Dae-Sik
AU  - Lim DS
FAU - Lee, Jinseon
AU  - Lee J
FAU - Kim, Hojoong
AU  - Kim H
FAU - Kim, Jhingook
AU  - Kim J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (DNA, Neoplasm)
RN  - 0 (RASSF1 protein, human)
RN  - 0 (Tumor Suppressor Proteins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Biomarkers, Tumor/analysis
MH  - Carcinoma, Non-Small-Cell Lung/genetics/mortality/*pathology/surgery
MH  - DNA Methylation
MH  - DNA, Neoplasm/genetics
MH  - Female
MH  - Genes, Tumor Suppressor
MH  - Humans
MH  - Lung Neoplasms/genetics/mortality/*pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Survival Analysis
MH  - Tumor Suppressor Proteins/analysis/*genetics
EDAT- 2005/02/09 09:00
MHDA- 2005/07/06 09:00
CRDT- 2005/02/09 09:00
PHST- 2005/02/09 09:00 [pubmed]
PHST- 2005/07/06 09:00 [medline]
PHST- 2005/02/09 09:00 [entrez]
AID - 10.1002/ijc.20916 [doi]
PST - ppublish
SO  - Int J Cancer. 2005 Jul 1;115(4):575-81. doi: 10.1002/ijc.20916.